Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 7/20 | 0.33 |
| ▸ | MMP10 | P09238 | 4/20 | 0.31 |
| ▸ | MMP8 | P22894 | 4/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901046 | 0.93 | CYP2C9 (0.37) | KCNH2MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL9942971 | 0.92 | KCNH2 (0.35) | KCNH2MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL9942882 | 0.90 | RORC (0.32) | KCNH2MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL9942869 | 0.89 | MMP13 (0.35) | KCNH2MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL9904915 | 0.84 | CYP2C9 (0.38) | KCNH2MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL9904934 | 0.84 | MMP13 (0.36) | KCNH2MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL9942948 | 0.83 | KCNH2 (0.43) | KCNH2CYP2C9MEN1KMT2A | |
| SCHEMBL9942931 | 0.83 | KCNH2 (0.34) | KCNH2MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL9904945 | 0.82 | CYP2C9 (0.40) | KCNH2MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL9942893 | 0.81 | CYP2C9 (0.39) | KCNH2MMP13MMP10MMP8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649077-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-10-16 | — | — | EP | claimed |
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | claimed |
| WO-2012078834-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | claimed |
| US-8835411-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835411-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| WO-2012078834-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309698-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | KCNH2 3969/4885MMP13 4137/4885MMP10 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.